NAFLD: Challenges and opportunities to address the public health problem in Latin America

Imagem de Miniatura
Arquivos
art_PABLO_NAFLD_Challenges_and_opportunities_to_address_the_public_2021.PDF (830.83 KB)
Citações na Scopus
17
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER ESPANA
Autores
PABLO, Arab Juan
ANTONIO, Diaz Luis
MELISA, Dirchwolf
MARK, Henry E.
LAZARUS, Jeffrey V.
VAUGHAN, Elly
MENDEZ-SANCHEZ, Nahum
GADANO, Adrian
ARRESE, Marco
Citação
ANNALS OF HEPATOLOGY, v.24, article ID 100359, 5p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Non-alcoholic fatty liver disease (NAFLD) is reaching epidemic proportions worldwide. Collectively, Latin American countries have some of the highest obesity rates in the world and the fastest-growing prevalence of type 2 diabetes mellitus (T2DM). Since obesity and T2DM are intrinsically linked with NAFLD, epidemiological projections are worrisome. In addition to this adverse epidemiological setting, the region of Latin America faces unique challenges and obstacles to addressing the growing burden of NAFLD. In this article, on the occasion of the International NASH Day on June 10, 2021, we describe the main challenges and opportunities to improve care of people living with NAFLD in Latin America. Among the major challenges to be tackled are: lack of disease awareness, limited educational opportunities for healthcare personnel and general public, health system fragmentation, and lack of effective strategies for the prevention and effective treatment of NAFLD and common comorbidities, namely obesity and T2DM. Wide dissemination of current concepts on NAFLD, and extensive collaboration between scientific societies, governments, non-governmental organizations, pharmaceutical industry, and other stakeholders is urgently needed to advance the NAFLD public health policies agenda that allows us to address this disease with a whole of society approach. (c) 2021 Published by Elsevier Espa?a, S.L.U. on behalf of Fundaci?n Cl?nica M?dica Sur, A.C. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
Palavras-chave
Non-alcoholic steatohepatitis, NASH, Non-alcoholic fatty liver disease, NAFLD, MAFLD, Public policies
URI
https://observatorio.fm.usp.br/handle/OPI/42207
Referências
  1. Alexander M, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1103-x
  2. Ampuero J, 2020, CLIN GASTROENTEROL H, V18, P216, DOI 10.1016/j.cgh.2019.05.051
  3. [Anonymous], 2003, HEPATOLOGY, V37, P244
  4. Bergqvist CJ, 2013, INTERN MED J, V43, P247, DOI 10.1111/j.1445-5994.2012.02848.x
  5. Blais P, 2015, AM J GASTROENTEROL, V110, P10, DOI 10.1038/ajg.2014.134
  6. Boursier J, 2021, JHEP REP, V3, DOI 10.1016/j.jhepr.2020.100219
  7. Boutari C, 2021, METABOLISM, V122, DOI 10.1016/j.metabol.2021.154781
  8. Bril F, 2017, DIABETES CARE, V40, P419, DOI 10.2337/dc16-1787
  9. Castera L, 2019, GASTROENTEROLOGY, V156, P1264, DOI 10.1053/j.gastro.2018.12.036
  10. Chalasani N, 2018, HEPATOLOGY, V67, P328, DOI 10.1002/hep.29367
  11. Eslam M, 2020, J HEPATOL, V73, P202, DOI 10.1016/j.jhep.2020.03.039
  12. Eslam M, 2020, GASTROENTEROLOGY, V158, P1999, DOI 10.1053/j.gastro.2019.11.312
  13. Fouad Y, 2021, J HEPATOL, V74, P1254, DOI 10.1016/j.jhep.2020.12.035
  14. Gallardo-Rincon H, 2021, PRIM CARE DIABETES, V15, P352, DOI 10.1016/j.pcd.2020.10.001
  15. Hardy T, 2020, CONTEMP CLIN TRIALS, V98, DOI 10.1016/j.cct.2020.106175
  16. Lazarus JV, 2020, J HEPATOL, V72, P14, DOI 10.1016/j.jhep.2019.08.027
  17. Lonardo A, 2021, ADV THER, V38, P2130, DOI 10.1007/s12325-021-01690-1
  18. Marciano S, 2021, Rev Gastroenterol Mex (Engl Ed), DOI 10.1016/j.rgmx.2020.08.006
  19. McPherson S, 2017, AM J GASTROENTEROL, V112, P740, DOI 10.1038/ajg.2016.453
  20. Mendez-Sanchez N, 2021, J HEPATOL, V75, P221, DOI 10.1016/j.jhep.2021.04.021
  21. Mendez-Sanchez N, 2021, LANCET GASTROENTEROL, V6, P65, DOI [10.1016/S2468-1253(20)30340-x, 10.1016/S2468-1253(20)30340-X]
  22. Mendez-Sanchez N, 2018, AM J GASTROENTEROL, V113, P1274, DOI 10.1038/s41395-018-0047-2
  23. Mendizabal M, 2017, LIVER TRANSPLANT, V23, P1210, DOI 10.1002/lt.24793
  24. O'Hara J, 2020, JHEP REP, V2, DOI 10.1016/j.jhepr.2020.100142
  25. Ofosu A, 2018, ANN GASTROENTEROL, V31, P288, DOI 10.20524/aog.2018.0240
  26. Arab JP, 2020, ANN HEPATOL, V19, P674, DOI 10.1016/j.aohep.2020.09.006
  27. Palacios C, 2021, PUBLIC HEALTH NUTR, P1
  28. Patel PJ, 2018, INTERN MED J, V48, P144, DOI 10.1111/imj.13667
  29. Pinto Marques Souza de Oliveira Claudia, 2019, Clin Liver Dis (Hoboken), V13, P39, DOI 10.1002/cld.759
  30. Powell EE, 2021, LANCET, V397, P2212, DOI 10.1016/S0140-6736(20)32511-3
  31. Sanyal AJ, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1149-9
  32. Sepulveda-Villegas M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0208926
  33. Singh A, 2020, DIGEST DIS SCI, V65, P978, DOI 10.1007/s10620-019-05700-9
  34. The Economist Intelligence Unit, 2021, NAFLD SOUND AL GLOB
  35. Treeprasertsuk S, 2012, LIVER INT, V32, P945, DOI 10.1111/j.1478-3231.2011.02753.x
  36. Younossi Z, 2019, HEPATOLOGY, V69, P2672, DOI 10.1002/hep.30251
  37. Younossi ZM, 2019, J HEPATOL, V70, P531, DOI 10.1016/j.jhep.2018.10.033
  38. Zambrano-Huailla R, 2020, ANN HEPATOL, V19, P622, DOI 10.1016/j.aohep.2020.08.066
  39. Zelber-Sagi S, 2017, WORLD J GASTROENTERO, V23, P1881, DOI 10.3748/wjg.v23.i10.1881

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - ODS/03